Jaguar Health, Inc. (JAGX)
| Market Cap | 805.18K -75.9% |
| Revenue (ttm) | 29.57M +156.0% |
| Net Income | -50.13M |
| EPS | -262.29 |
| Shares Out | 603.13K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,666 |
| Open | 1.950 |
| Previous Close | 1.950 |
| Day's Range | 1.260 - 1.975 |
| 52-Week Range | 1.310 - 92.750 |
| Beta | -0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsNews
Jaguar Health Registration statement: Registration filing
Jaguar Health filed a registration statement on July 16, 2026, providing details about a securities offering with the SEC.
Jaguar Health Registration statement: Registration filing
Jaguar Health filed a registration statement on July 16, 2026, providing details about a securities offering with the SEC.
Jaguar Health files to sell 5.52M shares of voting common stock for holders
06:03 EDT Jaguar Health (JAGX) files to sell 5.52M shares of voting common stock for holders
Jaguar Health files to sell 40.8M shares of voting common stock for holders
06:04 EDT Jaguar Health (JAGX) files to sell 40.8M shares of voting common stock for holders
Jaguar Health provides recap of presentations of crofelemer at ESPGHAN
Jaguar Health (JAGX) provided a recap of presentations of the oral liquid crofelemer as adjunctive therapy in pediatric intestinal failure, IF, patients at the 58th Annual European Society for Pediatr...
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of stu...
Jaguar Health announces conversion of Series O convertible preferred stock
Jaguar Health (JAGX) hereby notifies holders of its Series O Convertible Preferred Stock, par value $0.0001 per share, that the Company has exercised its right to cause the optional conversion…
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases Reminder: Two crofelemer presentations in pediatric intestinal failure pat...
Jaguar Health Transcript: Life Sciences Virtual Investor Forum
A rare disease-focused strategy is driving near-term catalysts, with crofelemer advancing through global trials for intestinal failure and MVID, targeting NDA filing in 2027. Recent clinical data show significant reductions in parenteral support, and major licensing and partnership deals support ongoing innovation.
Jaguar Health completes submission of NADA to U.S. FDA for crofelemer
Jaguar Health (JAGX) announced that the company has completed submission of its New Animal Drug Application, NADA, to the U.S. Food and Drug Administration’s Center for Veterinary Medicine for full…
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / Ju...
Jaguar Health initiates process to explore, review strategic alternatives
Jaguar Health (JAGX) announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value and aligned with…
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal...
Magdalena Biosciences announces results from preclinical study of coca
Jaguar Health (JAGX) announced that the results of a preclinical study initiated by Magdalena Biosciences, a US-based joint venture formed by Jaguar and Canada-based Filament Health (FLHLF), demonstra...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("J...
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two cr...
Jaguar Health Transcript: Emerging Growth Conference 93
A year of transformation is underway, driven by a $38M non-dilutive licensing deal and a strategic focus on rare diseases. Crofelemer’s new formulation shows up to 37% reduction in parenteral support for MVID, with regulatory filings and key data readouts expected within 12 months.
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jagu...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health says research in ethnobotanical medicine helps advance crofelemer
Jaguar Health (JAGX) and family company Napo Pharmaceuticals highlighted how the Company’s long-standing research in ethnobotanical medicine, sustainable harvesting, and regulatory drug development un...
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulat...
Jaguar Health Transcript: Lytham Partners Spring 2026 Investor Conference
A transformative out-license deal is fueling focused R&D on rare intestinal failure diseases, with crofelemer showing strong efficacy and safety in reducing parenteral support for MVID and short bowel syndrome. NDA filing for MVID is targeted for mid-2027.
Jaguar Health regains compliance with Nasdaq Listing Rule
Jaguar Health (JAGX) announced that on May 26, 2026, the Company received formal notice from The Nasdaq Stock Market that Jaguar has regained compliance with Nasdaq Listing Rule 5550(a)(2). Published…
Jaguar Health Compliant with Nasdaq Bid Price Rule
JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on ...
Jaguar Health Earnings Call Transcript: Q1 2026
Net revenue soared 816% year-over-year in Q1 2026, driven by a major out-license deal, while strategic focus shifted to rare disease drug development. Clinical milestones and non-dilutive funding position the company for future growth.